CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
IPO Year: 2022
Exchange: NASDAQ
Website: https://www.cincor.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/7/2022 | $22.00 | Overweight | Barclays |
| 11/29/2022 | Outperform → Perform | Oppenheimer | |
| 11/29/2022 | $60.00 → $22.00 | Overweight → Equal-Weight | Morgan Stanley |
| 10/28/2022 | $67.00 | Buy | Goldman |
| 8/22/2022 | $73.00 | Overweight | Piper Sandler |
| 2/1/2022 | Outperform | Evercore ISI | |
| 2/1/2022 | $30.00 | Outperform | Oppenheimer |
| 2/1/2022 | $27.00 | Overweight | Morgan Stanley |
| 2/1/2022 | $30.00 | Buy | Jefferies |
Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. "Following our strategic reprioritization to focus the company on maximizing the growth potential of
Primary endpoint in Intention to Treat (ITT) was not met despite large absolute reductions in Systolic Blood Pressure (SBP) 12.6 mmHg placebo-adjusted reduction in SBP with 2 mg baxdrostat in a pre-specified subgroup that represents approximately 81-89% of the U.S. hypertension population (nominal p-value = 0.001) Safety profile and tolerability consistent with BrigHtn Phase 2 data; no patient discontinued due to treatment-related adverse events; low hyperkalemia incidence HALO in combination with BrigHtn informs the dose and study populations anticipated to be recruited into Phase 3 trials pending confirmation by FDA at planned end of Phase 2 meeting in January 2023; Phase 3 trials expec
Aldosterone and renin biomarker activity clinically demonstrate how baxdrostat mechanistically achieves selective blood pressure lowering effects with no impact on cortisol 20.3 mmHg reduction in systolic blood pressure, or 11 mmHg (p-value < 0.0001) placebo-adjusted decline at the 2 mg dose Well-tolerated profile and differentiated mechanism of action supports combination approaches Conference call and live webcast Tuesday November 8th, 2022 at 7 AM Eastern Time WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. ("CinCor") announced the presentation today of Phase 2 data from its BrigHtn trial as part of the late-breaking science session at the 2022 American Heart A
Successfully met the primary endpoint in the BrigHtn trial, delivering a 20.3 mmHg reduction in systolic blood pressure (SBP), or an 11 mmHg (p-value < 0.0001) decline on a placebo-adjusted basis, at 2 mg dose Independent Data Review Committee determined that the trial met pre-specified statistical criteria of overwhelming efficacy at the highest dose allowing completion of the trial with 275 patients randomized Dose-dependent reduction in SBP observed Compelling safety and tolerability profile Conference call and live webcast today at 8:30 AM Eastern Time WALTHAM, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. ("CinCor") announced today the topline results and success
BrigHtn Phase 2 study with CIN-107 for Resistant Hypertension Enrollment Complete with Topline Results Expected in 2H 2022 Topline Data from HALO Phase 2 study with CIN-107 for Uncontrolled Hypertension Expected in 2H 2022 Mason Freeman, M.D. named Chief Medical Officer Conference call and live webcast today at 8:30 AM Eastern Time BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ:CINC) today announced financial results for the fourth quarter and full-year ended December 31, 2021 and provided a corporate update. "The past year was highly successful and foundational for CinCor. We advanced our pipeline, broadened and strengthened our team and established a solid b
BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ:CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced that it will report its fourth quarter and full year 2021 financial results before the open of the U.S. financial markets on Tuesday, March 22, 2022. Following the announcement, the Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information: Date:Tuesday, March 22, 2022Time:8:30 AM Eastern TimeDomestic:
-- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent
- venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo
Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. "Following our strategic reprioritization to focus the company on maximizing the growth potential of
SAN FRANCISCO and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- 5AM Ventures is pleased that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. REZZAYO is the first new treatment option approved for patients with candidemia and invasive candidiasis in over a decade. REZZAYO was developed by Cidara Therapeutics, Inc. (NASDAQ:CDTX), a company seeded and then supported by 5AM Ventures through its Series A and Series B rounds. 5AM's Scott Rocklage served as chair of the board of directors from the company's inception in 2012 through 2019. "Su
WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. ("CinCor" or the "Company") announced today completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration ("FDA") on the anticipated Phase 3 program for baxdrostat in hypertension. Baxdrostat is a once daily potentially first-in-class, highly selective aldosterone synthase inhibitor. On February 17, 2023, the Company received the official meeting minutes from the End-of-Phase 2 meeting with the FDA held on January 18, 2023 reflecting that the FDA has agreed with the Company on (1) the dosing cohorts to be used in the planned Phase 3 program, (2) the size of the required treated patient population fo
WALTHAM, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ:CINC) today announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed to acquire CinCor. Marc de Garidel, Chief Executive Officer at CinCor, said: "We are excited about the proposed acquisition of CinCor Pharma by AstraZeneca as we believe it offers the prospect of accelerating the development timeline and expanding the breadth of benefits patients with cardiorenal diseases might obtain from baxdrostat, if approved. CinCor is committed to ensuring a smooth transition of the development responsibilities to AstraZeneca once the acquisition is consummated. Thank y
Primary endpoint in Intention to Treat (ITT) was not met despite large absolute reductions in Systolic Blood Pressure (SBP) 12.6 mmHg placebo-adjusted reduction in SBP with 2 mg baxdrostat in a pre-specified subgroup that represents approximately 81-89% of the U.S. hypertension population (nominal p-value = 0.001) Safety profile and tolerability consistent with BrigHtn Phase 2 data; no patient discontinued due to treatment-related adverse events; low hyperkalemia incidence HALO in combination with BrigHtn informs the dose and study populations anticipated to be recruited into Phase 3 trials pending confirmation by FDA at planned end of Phase 2 meeting in January 2023; Phase 3 trials expec
WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ:CINC) today announced that company management will present at the following investor conferences in November: Event:Piper Sandler 34th Annual Healthcare ConferenceDate:November 29 – December 1, 2022Location:Lotte New York Palace in New York, New YorkPresentation:Tuesday, November 29, 2022 at 1:30pm ESTWebcast:https://event.webcasts.com/starthere.jsp?ei=1585686&tp_key=3261cabcd6 Event:Evercore ISI 5th Annual HealthCONx ConferenceDate:November 30 – December 1, 2022Location:VirtualPresentation:Thursday, December 1, 2022 at 3:30pm ESTWebcast:https://wsw.com/webcast/evercore29/cinc/2336910 The CinCor management team
WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ:CINC) today announced that company management will participate at the Jefferies London Healthcare Conference taking place on November 15-17, 2022 in London, United Kingdom. The presentation information is below: Jefferies London Healthcare ConferencePresentation:Wednesday, November 16, 2022 at 5 PM GMTLocation:Track 2 – Room, Adelphi 2, Ground Level at the Waldorf Hilton The CinCor management team will participate in one-on-one investor meetings during the event. Investors interested in meeting with CinCor at the conference should contact their Jefferies representative. About CinCorCinCor, founded in 2018, i
Aldosterone and renin biomarker activity clinically demonstrate how baxdrostat mechanistically achieves selective blood pressure lowering effects with no impact on cortisol 20.3 mmHg reduction in systolic blood pressure, or 11 mmHg (p-value < 0.0001) placebo-adjusted decline at the 2 mg dose Well-tolerated profile and differentiated mechanism of action supports combination approaches Conference call and live webcast Tuesday November 8th, 2022 at 7 AM Eastern Time WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. ("CinCor") announced the presentation today of Phase 2 data from its BrigHtn trial as part of the late-breaking science session at the 2022 American Heart A
Barclays initiated coverage of CinCor Pharma with a rating of Overweight and set a new price target of $22.00
Oppenheimer downgraded CinCor Pharma from Outperform to Perform
Morgan Stanley downgraded CinCor Pharma from Overweight to Equal-Weight and set a new price target of $22.00 from $60.00 previously
Goldman initiated coverage of CinCor Pharma with a rating of Buy and set a new price target of $67.00
Piper Sandler initiated coverage of CinCor Pharma with a rating of Overweight and set a new price target of $73.00
Evercore ISI initiated coverage of CinCor Pharma with a rating of Outperform
Oppenheimer initiated coverage of CinCor Pharma with a rating of Outperform and set a new price target of $30.00
Morgan Stanley initiated coverage of CinCor Pharma with a rating of Overweight and set a new price target of $27.00
Jefferies initiated coverage of CinCor Pharma with a rating of Buy and set a new price target of $30.00
CinCor Pharma, Inc. ("CinCor" or the "Company") announced today completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration ("FDA") on the anticipated Phase 3 program for baxdrostat in hypertension. Baxdrostat is a once daily potentially first-in-class, highly selective aldosterone synthase inhibitor. On February 17, 2023, the Company received the official meeting minutes from the End-of-Phase 2 meeting with the FDA held on January 18, 2023 reflecting that the FDA has agreed with the Company on (1) the dosing cohorts to be used in the planned Phase 3 program, (2) the size of the required treated patient population for purposes of determining safety and (3) the over
Over the past 3 months, 6 analysts have published their opinion on CinCor Pharma (NASDAQ:CINC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 2 3 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 1 0 0 2M Ago 0 2 1 0 0 3M Ago 1 0 0 0 0 These 6 analysts have an average price target of $32.33 versus the current price of CinCor Pharma at $28.75, implying upside. Below is a summary of how these 6 analysts rated CinCor Pharma over the past 3 months. The greater the number of bullish
Barclays analyst Leon Wang downgrades CinCor Pharma (NASDAQ:CINC) from Overweight to Equal-Weight and raises the price target from $22 to $31.
Morgan Stanley analyst Jeffrey Hung maintains CinCor Pharma (NASDAQ:CINC) with a Equal-Weight and raises the price target from $22 to $30.
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Monday. The Dow traded up 0.14% to 33,678.48 while the NASDAQ rose 1.63% to 10,741.65. The S&P 500 also rose, gaining, 0.63% to 3,919.83. Check This Out: Bitcoin Tops This Key Level; Gala, Solana Among Top Gainers Leading and Lagging Sectors Information technology shares gained by 2.8% on Monday. Meanwhile, top gainers in the sector included Duck Creek Technologies, Inc. (NASDAQ:DCT), up 47%, and Bitfarms Ltd. (NASDAQ:BITF), up 34%. In trading on Monday, health care shares fell by 0.5%. Top Headline Acuity Brands, Inc (NYSE:AYI) reported better-than-expected earnings
Gainers CinCor Pharma, Inc. (NASDAQ:CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash. Apexigen, Inc. (NASDAQ:APGN) jumped 111% to $1.99 after climbing more than 10% on Friday. Amryt Pharma plc (NASDAQ:AMYT) gained 106.7% to $14.49 after Chiesi Farmaceutici announced it will acquire the company for $14.50 per ADS plus contingent value rights of up to an additional $2.50 per ADS. Albireo Pharma, Inc. (NASDAQ:ALBO) shares climbed 92.9% to $44.03 after Ipsen announced it will acquire the company for $42 per share plus a contingent value right of $10 per share. Duck Creek Technologies, Inc. (NASDAQ:DCT) gained 47% to $19.1
Gainers CinCor Pharma (NASDAQ:CINC) shares increased by 148.0% to $29.22 during Monday's regular session. As of 12:30 EST, CinCor Pharma's stock is trading at a volume of 7.1 million, which is 1750.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.2 billion. Amryt Pharma (NASDAQ:AMYT) stock moved upwards by 109.14% to $14.64. Trading volume for Amryt Pharma's stock is 9.9 million as of 12:30 EST. This is 22502.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $936.5 million. Apexigen (NASDAQ:APGN) stock moved upwards by 108.54% to $1.83. The current volume of 67.7 milli
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Monday. The Dow traded up 0.70% to 33,865.87 while the NASDAQ rose 2.09% to 10,790.16. The S&P 500 also rose, gaining, 1.25% to 3,943.66. Check This Out: Bitcoin Tops This Key Level; Gala, Solana Among Top Gainers Leading and Lagging Sectors Information technology shares gained by 2.8% on Monday. Meanwhile, top gainers in the sector included Duck Creek Technologies, Inc. (NASDAQ:DCT), up 47%, and Bitfarms Ltd. (NASDAQ:BITF), up 34%. In trading on Monday, health care shares fell by 0.4%. Top Headline Acuity Brands, Inc (NYSE:AYI) reported better-than-expected earnings and
U.S. stocks traded higher, with the Dow Jones gaining more than 150 points on Monday. Here are some big stocks recording losses in today’s session. CinCor Pharma, Inc. (NASDAQ:CINC) shares surged 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash. Amryt Pharma plc (NASDAQ:AMYT) jumped 106.7% to $14.49 after Chiesi Farmaceutici announced it will acquire the company for $14.50 per ADS plus contingent value rights of up to an additional $2.50 per ADS. Albireo Pharma, Inc. (NASDAQ:ALBO) shares gained 92.9% to $44.03 after Ipsen announced it will acquire the company for $42 per share plus a contingent value right of $10 per share. Duck Creek Tec
U.S. stocks traded higher this morning, with the Dow Jones gaining around 150 points on Monday. Following the market opening Monday, the Dow traded up 0.49% to 33,796.59 while the NASDAQ rose 1.22% to 10,698.66. The S&P 500 also rose, gaining, 0.70% to 3,922.36. Check This Out: Bitcoin Tops This Key Level; Gala, Solana Among Top Gainers Leading and Lagging Sectors Information technology shares gained by 1.6% on Monday. Meanwhile, top gainers in the sector included Duck Creek Technologies, Inc. (NASDAQ:DCT), up 47%, and Paya Holdings Inc. (NASDAQ:PAYA), up 24%. In trading on Monday, consumer staples shares fell by 0.1%. Top Headline Acuity Brands, Inc (NYSE:AYI) reported better
8-K - CinCor Pharma, Inc. (0001868734) (Filer)
25-NSE - CinCor Pharma, Inc. (0001868734) (Subject)
SC 14D9/A - CinCor Pharma, Inc. (0001868734) (Subject)
SC TO-T/A - CinCor Pharma, Inc. (0001868734) (Subject)
SC 14D9/A - CinCor Pharma, Inc. (0001868734) (Subject)
SC TO-T/A - CinCor Pharma, Inc. (0001868734) (Subject)
8-K - CinCor Pharma, Inc. (0001868734) (Filer)
SC 14D9/A - CinCor Pharma, Inc. (0001868734) (Subject)
SC 14D9/A - CinCor Pharma, Inc. (0001868734) (Subject)
SC TO-T/A - CinCor Pharma, Inc. (0001868734) (Subject)
4 - CinCor Pharma, Inc. (0001868734) (Issuer)
4 - CinCor Pharma, Inc. (0001868734) (Issuer)
4 - CinCor Pharma, Inc. (0001868734) (Issuer)
4 - CinCor Pharma, Inc. (0001868734) (Issuer)
4 - CinCor Pharma, Inc. (0001868734) (Issuer)
4 - CinCor Pharma, Inc. (0001868734) (Issuer)
4 - CinCor Pharma, Inc. (0001868734) (Issuer)
4 - CinCor Pharma, Inc. (0001868734) (Issuer)
4 - CinCor Pharma, Inc. (0001868734) (Issuer)
4 - CinCor Pharma, Inc. (0001868734) (Issuer)
SC 13D/A - CinCor Pharma, Inc. (0001868734) (Subject)
SC 13D/A - CinCor Pharma, Inc. (0001868734) (Subject)
SC 13D/A - CinCor Pharma, Inc. (0001868734) (Subject)
SC 13D/A - CinCor Pharma, Inc. (0001868734) (Subject)
SC 13G - CinCor Pharma, Inc. (0001868734) (Subject)
SC 13D - CinCor Pharma, Inc. (0001868734) (Subject)
SC 13G/A - CinCor Pharma, Inc. (0001868734) (Subject)
SC 13D - CinCor Pharma, Inc. (0001868734) (Subject)
SC 13D/A - CinCor Pharma, Inc. (0001868734) (Subject)
SC 13G/A - CinCor Pharma, Inc. (0001868734) (Subject)